ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

– Seasoned medical leader becomes ADARx’s CMO to lead advancement of multiple clinical  development programs – 

SAN DIEGO, Calif. – April 2, 2024 – ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage  biotechnology company developing next generation RNA therapeutics, today announced the  appointment of Chris Storgard, MD, as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of experience across clinical development, clinical operations and pharmaceutical  drug development, from early stage through product approval and commercialization, at both  small and large biopharma companies. 

As CMO, Dr. Storgard will lead Clinical Research, Clinical Operations, Biometrics,  Pharmacovigilance and Medical Affairs. This newly-created position will lead efforts to advance  ADARx’s expanding pipeline of RNA targeting therapeutics, which are currently focused on  addressing diseases within three key areas: genetic disorders, cardiometabolic conditions and  central nervous system diseases. With 10 active programs in development, Dr. Storgard’s  leadership and strategic direction will be instrumental in driving the progression of these  programs, ultimately aiming to bring innovative treatments to patients in need. 

“We are honored to welcome Chris as Chief Medical Officer—his wealth of experience and deep  understanding of clinical research and operations will undoubtedly play a crucial role in steering  our robust pipeline of next-generation RNA programs towards successful clinical outcomes,”  said Zhen Li, PhD, Co-Founder, President and CEO of ADARx. “With his proven ability to build,  lead and inspire cross-functional teams to produce results leading to global regulatory  approvals, he brings invaluable expertise to our organization. Chris’s experience in the design,  development, and execution of early- to late-stage clinical trials will be critical at this time as we  advance several programs in multiple therapeutic categories, three of which are already in the  clinic. Chris’ appointment marks a significant milestone for ADARx and we look forward to  further realizing the full potential of our unique RNA platform in the clinic under his guidance.” 

“I am very enthusiastic about joining the ADARx team especially given the potential for its  clinical stage candidates that, I believe, have best-in-class profiles, and multiple expected near term milestones this year,” said Dr. Storgard. “Building on the company’s important progress to  date, I am eager to contribute my expertise and collaborate with the talented ADARx team to  continue to drive these programs forward, ultimately advancing our mission of delivering  innovative RNA medicines to improve patient outcomes.” 

Prior to joining ADARx, Dr. Storgard was the CMO at Heron Therapeutics, where he played a  pivotal role in driving clinical research and medical initiatives for all pipeline candidates and four  marketed products in oncology supportive care and acute care franchises. Prior to Heron, Dr.  Storgard was the CMO at Fate Therapeutics where he built and managed a multidisciplinary  clinical development organization to execute on clinical strategy, design and execution of all  clinical programs. Previously, Dr. Storgard was Vice President, Clinical Research and  Development at Ardea Biosciences (acquired by AstraZeneca), and also held increasingly  responsible positions at Biogen-Idec and Amgen. Prior to this, he was a Senior Associate  Consultant in the Division of Rheumatology at the Mayo School of Medicine, Mayo Clinic in  Minnesota, where he also served as an Assistant Professor and Member of the Molecular Medicine Program from 2001 to 2004. Dr. Storgard has a BSc in biology and an MD from the  University of Saskatchewan in Canada. Dr. Storgard completed a fellowship in rheumatology at  Scripps Clinic and Research Center in San Diego, CA. 

About ADARx Pharmaceuticals 

ADARx Pharmaceuticals, Inc. is a clinical stage biotechnology company committed to turning  cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA  delivery platforms and technology for silencing or editing target mRNA. ADARx has a growing  pipeline of RNA therapeutics for treating diseases across a range of therapeutic areas including  genetic, cardiovascular, complement-mediated and central nervous system diseases. Follow  ADARx on LinkedIn. 

ADARx Contacts 

Investors
Roselle Corbaley
(877) 232-7974
ir@adarx.com

Media
Michael Beyer
mike@redhousecomms.com